Last reviewed · How we verify
NCT07138989
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2 trial testing Valganciclovir Hydrochloride Tablets in Nasopharyngeal Cancinoma (NPC) in 10 participants. Not yet recruiting.
18 August 2026
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 19 August 2025 |
| Primary completion | 18 August 2026 |
| Estimated completion | 18 August 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- Valganciclovir Hydrochloride Tablets
- gemcitabine, cisplatin, and PD-1 antibody — full drug profile →
Conditions studied
- Nasopharyngeal Cancinoma (NPC) — all drugs for Nasopharyngeal Cancinoma (NPC) →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Nasopharyngeal Cancinoma (NPC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells. By combining EBV lytic induction strategy with standard chemo-immunotherapy, this study aims to create a synergistic anti-tumor effect and improve clinical outcomes for patients with recurrent/metastatic NPC (r/m NPC). This is a phase II, single-center, single-arm clinical trial designed to evaluate the efficacy and safety of a novel combination therapy in patients with r/m EBV-positive NPC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07138989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Cancinoma (NPC)
Currently open trials in the same condition.
- NCT07362979 — Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal C · Phase 2 · recruiting
- NCT07496190 — Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy · Phase 2 · recruiting
- NCT07325539 — LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC · Phase 2 · recruiting
- NCT07376603 — IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features · recruiting
- NCT07311772 — Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid · Phase 3 · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07138989 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 24 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07138989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing